Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Rogaine foam ANDA draws suit

This article was originally published in The Tan Sheet

Executive Summary

The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)
Advertisement

Related Content

Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says
Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS103440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel